Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.

British journal of clinical pharmacology - 1 Nov 1991

Wanwimolruk S, Chalcroft S

Abstract excerpt

The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine after a single dose (600 mg) of quinine sulphate was studied in eight extensive metabolizers (EM) and five poor metabolizers (PM). The mean elimination half-life of quinine in the PMs (10.2 +/- 1.6 (s.d.)h) was similar to that in the EMs (10.9 +/- 1.7 h). The oral clearance of quinine in the PM subjects was 0.092 +/-...

Topics

Adult
Debrisoquin
Female
Half-Life
Humans
Male
Oxidation-Reduction
Phenotype
Quinine

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 1954076
DOI: 10.1111/j.1365-2125.1991.tb03961.x
PMCID: PMC1368640

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-1954076-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.PMID 1954076Read ↗

Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.Semantic proximity Read ↗

Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population.Semantic proximity Read ↗

Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.Semantic proximity Read ↗

Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.Semantic proximity Read ↗

Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.Semantic proximity Read ↗

Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.Semantic proximity Read ↗

The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of chlorpropamide.Semantic proximity Read ↗

Polymorphic debrisoquin metabolism in a Turkish population.Semantic proximity Read ↗

Genetically determined adverse drug reactions involving metabolism.Semantic proximity Read ↗

3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.Semantic proximity Read ↗

Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.Semantic proximity Read ↗

Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.